|
1
|
American Cancer Society, . Cancer Facts
and Figures 2020. American Cancer Society; Atlanta, GA: 2020
|
|
2
|
Visini M, Giger R, Shelan M, Elicin O and
Anschuetz L: Predicting factors for oncological and functional
outcome in hypopharyngeal cancer. Laryngoscope. 131:E1543–E1549.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hall SF, Groome PA, Irish J and O'Sullivan
B: The natural history of patients with squamous cell carcinoma of
the hypopharynx. Laryngoscope. 118:1362–1371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prince ME and Ailles LE: Cancer stem cells
in head and neck squamous cell cancer. J Clin Oncol. 26:2871–2875.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clara JA, Monge C, Yang Y and Takebe N:
Targeting signalling pathways and the immune microenvironment of
cancer stem cells-a clinical update. Nat Rev Clin Oncol.
17:204–232. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan G, Boyle JO, Yang EK, Zhang F, Sacks
PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, et al:
Cyclooxygenase-2 expression is up-regulated in squamous cell
carcinoma of the head and neck. Cancer Res. 59:991–994.
1999.PubMed/NCBI
|
|
8
|
Camacho M, Leon X, Fernandez-Figueras MT,
Quer M and Vila L: Prostaglandin E(2) pathway in head and neck
squamous cell carcinoma. Head Neck. 30:1175–1181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mendes RA, Carvalho JF and Waal Iv: An
overview on the expression of cyclooxygenase-2 in tumors of the
head and neck. Oral Oncol. 45:e124–e128. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallo O, Masini E, Bianchi B, Bruschini L,
Paglierani M and Franchi A: Prognostic significance of
cyclooxygenase-2 pathway and angiogenesis in head and neck squamous
cell carcinoma. Hum Pathol. 33:708–714. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Itoh S, Matsui K, Furuta I and Takano Y:
Immunohistochemical study on overexpression of cyclooxygenase-2 in
squamous cell carcinoma of the oral cavity: Its importance as a
prognostic predictor. Oral Oncol. 39:829–835. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saba NF, Choi M, Muller S, Shin HJ,
Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen
ZG and Shin DM: Role of cyclooxygenase-2 in tumor progression and
survival of head and neck squamous cell carcinoma. Cancer Prev Res
(Phila). 2:823–829. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang CC, Tu HF, Wu CH, Chang HC, Chiang
WF, Shih NC, Lee YS, Kao SY and Chang KW: Up-regulation of HB-EGF
by the COX-2/PGE2 signaling associates with the cisplatin
resistance and tumor recurrence of advanced HNSCC. Oral Oncol.
56:54–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abrahao AC, Castilho RM, Squarize CH,
Molinolo AA, dos Santos-Pinto D Jr and Gutkind JS: A role for
COX2-derived PGE2 and PGE2-receptor subtypes in head and neck
squamous carcinoma cell proliferation. Oral Oncol. 46:880–887.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang B, Jia L, Guo Q, Ren H, Hu Y and Xie
T: Clinicopathological and prognostic significance of
cyclooxygenase-2 expression in head and neck cancer: A
meta-analysis. Oncotarget. 7:47265–47277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sekimizu M, Ozawa H, Saito S, Ikari Y,
Nakahara N, Nakamura S, Yoshihama K, Ito F, Watanabe Y, Imanishi Y,
et al: Cyclo-oxygenase-2 expression is associated with lymph node
metastasis in oropharyngeal squamous cell carcinoma under the new
TNM classification. Anticancer Res. 39:5623–5630. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujii R, Imanishi Y, Shibata K, Sakai N,
Sakamoto K, Shigetomi S, Habu N, Otsuka K, Sato Y, Watanabe Y, et
al: Restoration of E-cadherin expression by selective Cox-2
inhibition and the clinical relevance of the
epithelial-to-mesenchymal transition in head and neck squamous cell
carcinoma. J Exp Clin Cancer Res. 33:402014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watanabe Y, Imanishi Y, Ozawa H, Sakamoto
K, Fujii R, Shigetomi S, Habu N, Otsuka K, Sato Y, Sekimizu M, et
al: Selective EP2 and Cox-2 inhibition suppresses cell migration by
reversing epithelial-to-mesenchymal transition and Cox-2
overexpression and E-cadherin downregulation are implicated in neck
metastasis of hypopharyngeal cancer. Am J Transl Res. 12:1096–1113.
2020.PubMed/NCBI
|
|
19
|
Shi C, Guan Y, Zeng L, Liu G, Zhu Y, Xu H,
Lu Y, Liu J, Guo J, Feng X, et al: High COX-2 expression
contributes to a poor prognosis through the inhibition of
chemotherapy-induced senescence in nasopharyngeal carcinoma. Int J
Oncol. 53:1138–1148. 2018.PubMed/NCBI
|
|
20
|
Saikawa Y, Sugiura T, Toriumi F, Kubota T,
Suganuma K, Isshiki S, Otani Y, Kumai K and Kitajima M:
Cyclooxygenase-2 gene induction causes CDDP resistance in colon
cancer cell line, HCT-15. Anticancer Res. 24((5A)): 2723–2728.
2004.PubMed/NCBI
|
|
21
|
Patel VA, Dunn MJ and Sorokin A:
Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol
Chem. 277:38915–38920. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Raju U, Ariga H, Dittmann K, Nakata E, Ang
KK and Milas L: Inhibition of DNA repair as a mechanism of enhanced
radioresponse of head and neck carcinoma cells by a selective
cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol
Phys. 63:520–528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu M, Guan J, Li C, Gunter S, Nusrat L, Ng
S, Dhand K, Morshead C, Kim A and Das S: Aberrantly activated Cox-2
and Wnt signaling interact to maintain cancer stem cells in
glioblastoma. Oncotarget. 8:82217–82230. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deng Y, Su Q, Mo J, Fu X, Zhang Y and Lin
EH: Celecoxib downregulates CD133 expression through inhibition of
the Wnt signaling pathway in colon cancer cells. Cancer Invest.
31:97–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang C, Chen Y, Liu H, Yang J, Song X,
Zhao J, He N, Zhou CJ, Wang Y, Huang C and Dong Q: Celecoxib
targets breast cancer stem cells by inhibiting the synthesis of
prostaglandin E2 and down-regulating the Wnt pathway
activity. Oncotarget. 8:115254–115269. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Q, Yuan W, Tong D, Liu G, Lan W, Zhang
D, Xiao H, Zhang Y, Huang Z, Yang J, et al: Metformin represses
bladder cancer progression by inhibiting stem cell repopulation via
COX2/PGE2/STAT3 axis. Oncotarget. 7:28235–28246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akutsu Y, Hanari N, Yusup G,
Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y
and Matsubara H: COX2 expression predicts resistance to
chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg
Oncol. 18:2946–2951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shaik MS, Chatterjee A, Jackson T and
Singh M: Enhancement of antitumor activity of docetaxel by
celecoxib in lung tumors. Int J Cancer. 118:396–404. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Janakiraman H, House RP, Talwar S,
Courtney SM, Hazard ES, Hardiman G, Mehrotra S, Howe PH, Gangaraju
V and Palanisamy V: Repression of caspase-3 and RNA-binding protein
HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral
squamous cell carcinoma. Oncogene. 36:3137–3148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choe MS, Chen Z, Klass CM, Zhang X and
Shin DM: Enhancement of docetaxel-induced cytotoxicity by blocking
epidermal growth factor receptor and cyclooxygenase-2 pathways in
squamous cell carcinoma of the head and neck. Clin Cancer Res.
13:3015–3023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen KH, Hsu CC, Song WS, Huang CS, Tsai
CC, Kuo CD, Hsu HS, Tsai TH, Tsai CY, Woung LC, et al: Celecoxib
enhances radiosensitivity in medulloblastoma-derived CD133-positive
cells. Childs Nerv Syst. 26:1605–1612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tong D, Liu Q, Wang LA, Xie Q, Pang J,
Huang Y, Wang L, Liu G, Zhang D, Lan W and Jiang J: The roles of
the COX2/PGE2/EP axis in therapeutic resistance. Cancer Metastasis
Rev. 37:355–368. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vinogradov S and Wei X: Cancer stem cells
and drug resistance: The potential of nanomedicine. Nanomedicine
(Lond). 7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF,
O'Sullivan B, He Z, Peng Y, Tan AC, et al: Caspase 3-mediated
stimulation of tumor cell repopulation during cancer radiotherapy.
Nat Med. 17:860–866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Majumder M, Xin X, Liu L, Tutunea-Fatan E,
Rodriguez-Torres M, Vincent K, Postovit LM, Hess D and Lala PK:
COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT
axis. Stem Cells. 34:2290–2305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo Z, Jiang JH, Zhang J, Yang HJ, Yang
FQ, Qi YP, Zhong YP, Su J, Yang RR, Li LQ and Xiang BD: COX-2
promotes migration and invasion by the side population of cancer
stem cell-like hepatocellular carcinoma cells. Medicine
(Baltimore). 94:e18062015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen J, Shen P, Zhang XC, Zhao MD, Zhang
XG and Yang L: Efficacy and safety profile of celecoxib for
treating advanced cancers: A meta-analysis of 11 randomized
clinical trials. Clin Ther. 36:1253–1263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Edelman MJ, Wang X, Hodgson L, Cheney RT,
Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J,
et al: Phase III randomized, placebo-controlled, double-blind trial
of celecoxib in addition to standard chemotherapy for advanced
non-small-cell lung cancer with cyclooxygenase-2 overexpression:
CALGB 30801 (Alliance). J Clin Oncol. 35:2184–2192. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mohammadianpanah M, Razmjou-Ghalaei S,
Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M,
Omidvari S, Mosalaei A and Mosleh-Shirazi MA: Efficacy and safety
of concurrent chemoradiation with weekly cisplatin +/- low-dose
celecoxib in locally advanced undifferentiated nasopharyngeal
carcinoma: A phase II–III clinical trial. J Cancer Res Ther.
7:442–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gulyas M, Mattsson JSM, Lindgren A, Ek L,
Lamberg Lundström K, Behndig A, Holmberg E, Micke P and Bergman B;
Swedish Lung Cancer Study Group, : COX-2 expression and effects of
celecoxib in addition to standard chemotherapy in advanced
non-small cell lung cancer. Acta Oncol. 57:244–250. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O'Callaghan G and Houston A: Prostaglandin
E2 and the EP receptors in malignancy: Possible therapeutic
targets? Br J Pharmacol. 172:5239–5250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hoshikawa H, Goto R, Mori T, Mitani T and
Mori N: Expression of prostaglandin E2 receptors in oral squamous
cell carcinomas and growth inhibitory effects of an EP3 selective
antagonist, ONO-AE3-240. Int J Oncol. 34:847–852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Markovic T, Jakopin Z, Dolenc MS and
Mlinaric-Rascan I: Structural features of subtype-selective EP
receptor modulators. Drug Discov Today. 22:57–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bai X, Wang J, Zhang L, Ma J, Zhang H, Xia
S, Zhang M, Ma X, Guo Y, Rong R, et al: Prostaglandin E2
receptor EP1-mediated phosphorylation of focal adhesion kinase
enhances cell adhesion and migration in hepatocellular carcinoma
cells. Int J Oncol. 42:1833–1841. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pan J, Yang Q, Shao J, Zhang L, Ma J, Wang
Y, Jiang BH, Leng J and Bai X: Cyclooxygenase-2 induced β1-integrin
expression in NSCLC and promoted cell invasion via the
EP1/MAPK/E2F-1/FoxC2 signal pathway. Sci Rep. 6:338232016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ma X, Kundu N, Ioffe OB, Goloubeva O,
Konger R, Baquet C, Gimotty P, Reader J and Fulton AM:
Prostaglandin E receptor EP1 suppresses breast cancer metastasis
and is linked to survival differences and cancer disparities. Mol
Cancer Res. 8:1310–1318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Amano H, Hayashi I, Endo H, Kitasato H,
Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto
Y, et al: Host prostaglandin E(2)-EP3 signaling regulates
tumor-associated angiogenesis and tumor growth. J Exp Med.
197:221–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pan MR, Hou MF, Chang HC and Hung WC:
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling
pathways to enhance lymphatic invasion of breast cancer cells. J
Biol Chem. 283:11155–11163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Obermajer N and Kalinski P: Key role of
the positive feedback between PGE(2) and COX2 in the biology of
myeloid-derived suppressor cells. Oncoimmunology. 1:762–764. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
af Forselles KJ, Root J, Clarke T, Davey
D, Aughton K, Dack K and Pullen N: In vitro and in vivo
characterization of PF-04418948, a novel, potent and selective
prostaglandin EP2 receptor antagonist. Br J Pharmacol.
164:1847–1856. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Solomon SD, McMurray JJ, Pfeffer MA,
Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E and
Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study
Investigators, : Cardiovascular risk associated with celecoxib in a
clinical trial for colorectal adenoma prevention. N Engl J Med.
352:1071–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
